- Home
- STTK vs IFRX Comparison
STTK vs IFRX Comparison
Compare STTK & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- IFRX
- Stock Information
- Founded
- STTK 2016
- IFRX 2007
- Country
- STTK United States
- IFRX Germany
- Employees
- STTK 44
- IFRX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- IFRX Health Care
- Exchange
- STTK Nasdaq
- IFRX Nasdaq
- Market Cap
- STTK 48.9M
- IFRX 53.5M
- IPO Year
- STTK 2020
- IFRX 2017
- Fundamental
- Price
- STTK $1.02
- IFRX $0.86
- Analyst Decision
- STTK Hold
- IFRX Strong Buy
- Analyst Count
- STTK 5
- IFRX 4
- Target Price
- STTK $2.00
- IFRX $7.75
- AVG Volume (30 Days)
- STTK 5.2M
- IFRX 210.3K
- Earning Date
- STTK 08-14-2025
- IFRX 08-07-2025
- Dividend Yield
- STTK N/A
- IFRX N/A
- EPS Growth
- STTK N/A
- IFRX N/A
- EPS
- STTK N/A
- IFRX N/A
- Revenue
- STTK $2,997,000.00
- IFRX $191,224.00
- Revenue This Year
- STTK N/A
- IFRX N/A
- Revenue Next Year
- STTK N/A
- IFRX $1,276.37
- P/E Ratio
- STTK N/A
- IFRX N/A
- Revenue Growth
- STTK N/A
- IFRX 54.36
- 52 Week Low
- STTK $0.69
- IFRX $0.71
- 52 Week High
- STTK $3.95
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- STTK 61.64
- IFRX 49.76
- Support Level
- STTK $0.71
- IFRX $0.84
- Resistance Level
- STTK $1.05
- IFRX $0.95
- Average True Range (ATR)
- STTK 0.09
- IFRX 0.07
- MACD
- STTK 0.03
- IFRX 0.01
- Stochastic Oscillator
- STTK 69.18
- IFRX 57.94
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.